The clinical effect of antiviral therapy in patients with hepatitis B virus‐related decompensated cirrhosis and undetectable DNA
- 20 February 2023
- journal article
- research article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 38 (5), 716-723
- https://doi.org/10.1111/jgh.16132
Abstract
Background and AimAntiviral therapy (AVT) is the mainstay of hepatitis B virus (HBV) management. We investigated whether AVT improves the outcomes of HBV-related decompensated cirrhosis and undetectable HBV-DNA. MethodsBetween 2000 and 2017, treatment-naive patients with HBV-related decompensated cirrhosis and undetectable HBV-DNA were recruited from two tertiary hospitals. The endpoints included death and hepatocellular carcinoma (HCC). ResultsA total of 429 patients were analyzed (50 and 379 patients in the AVT and non-AVT groups, respectively). Patients in the AVT group were significantly younger and had higher alanine aminotransferase and alpha-fetoprotein levels than those in the non-AVT group (all P < 0.05). During follow-up (median 49.6 months), 98 patients died and 105 developed HCC. The cumulative incidence rates of death (2.0%, 4.1%, and 6.4%, and 4.9%, 7.2%, and 10.2% at 6 months, 1 year, and 2 years, respectively) and HCC (8.6%, 15.8%, and 26.4% vs 1.6%, 7.7%, and 24.4% at 1, 2, and 5 years, respectively) were statistically comparable between the AVT and non-AVT groups (all P > 0.05). Using Cox regression analysis, AVT was not significantly associated with death nor HCC (all P > 0.05). Similar results were observed after balancing baseline characteristics with inverse probability of treatment weighting. In the non-AVT group, the cumulative incidence rates of HBV-DNA detection at 6 months, 1 year, and 2 years were 2.0%, 3.1%, and 6.4%, respectively. ConclusionsAntiviral therapy did not attenuate the risk of death nor HCC in patients with HBV-related decompensated cirrhosis and undetectable HBV-DNA.Keywords
Funding Information
- Ministry of Trade, Industry and Energy (20013712)
- Ministry of Science and ICT, South Korea (2022R1I1A1A01065244)
This publication has 29 references indexed in Scilit:
- Genetic Landscape and Biomarkers of Hepatocellular CarcinomaGastroenterology, 2015
- Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targetsNature Genetics, 2015
- Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosisJournal of Hepatology, 2013
- Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infectionJournal of Hepatology, 2012
- Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapyJournal of Hepatology, 2012
- Trends in Waiting List Registration for Liver Transplantation for Viral Hepatitis in the United StatesGastroenterology, 2009
- Correlation between serum hepatitis B virus core‐related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patientsJournal of Medical Virology, 2008
- Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factorsJournal of Hepatology, 2008
- Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up studyHepatology International, 2007
- Hepatitis B Virus-Related Cirrhosis: Natural History and TreatmentSeminars in Liver Disease, 2006